Aclaris Therapts (ACRS)

$2.52 +0.20 (8.62%)
Market Cap 251.36M
Revenue (ttm) 18.72M
Net Income (ttm) -132.07M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -705.50%
Debt to Equity Ratio 0.00
Volume 2,433,900
Avg Vol 1,311,276
Day's Range N/A - N/A
Shares Out 108.35M
Stochastic %K 78%
Beta 0.43
Analysts Strong Sell
Price Target $7.86

Company Profile

Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. Its Contract Research segment provides laboratory services. The company also develops ATI-1777, a soft JA...

Industry: Biotechnology
Sector: Healthcare
Phone: 484 324 7933
Address:
701 Lee Road, Suite 103, Wayne, United States
StockScanners
StockScanners Nov. 15 at 4:17 AM
$ACRS keep watch if this holds above 2.45
0 · Reply
Bionco
Bionco Nov. 14 at 10:50 PM
$ACRS 189k shares changed hands in a single after-hours trade.
0 · Reply
OriginalTradeonrumor
OriginalTradeonrumor Nov. 14 at 9:07 PM
$ACRS picture perfect trading today!! Loving it !!
0 · Reply
StockDaddy68
StockDaddy68 Nov. 14 at 5:58 PM
$ACRS Very nice
0 · Reply
Bionco
Bionco Nov. 14 at 10:35 AM
$ACRS According to the 13G filing from yesterday, Adage sold a total of 2.92 million shares last week, accounting for the elevated trading volume and the stock's decline over four consecutive days.
1 · Reply
swingexpert
swingexpert Nov. 14 at 6:33 AM
$ACRS We need a catalyst for this to move—top-line Phase 1a results aren’t expected until late 2025, so it may trade sideways until then.
0 · Reply
Btolz
Btolz Nov. 13 at 7:59 PM
$ACRS
0 · Reply
Bionco
Bionco Nov. 13 at 4:32 PM
$ACRS Adage Capital Management recently sold approximately 3 million shares, exiting the group of ≥5% owners.
0 · Reply
StockDaddy68
StockDaddy68 Nov. 13 at 11:22 AM
$ACRS
0 · Reply
Sambo87
Sambo87 Nov. 13 at 10:12 AM
$ACRS
0 · Reply
Latest News on ACRS
Aclaris Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 6, 2025, 6:59 AM EST - 8 days ago

Aclaris Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Aclaris Therapeutics to Participate in Three November Healthcare Conferences

Oct 29, 2025, 7:30 AM EDT - 16 days ago

Aclaris Therapeutics to Participate in Three November Healthcare Conferences

Aclaris Therapeutics, Inc. - Special Call

Oct 14, 2025, 5:46 PM EDT - 4 weeks ago

Aclaris Therapeutics, Inc. - Special Call

Aclaris Therapeutics to Host In-Person and Webcast R&D Day, “Patient Focused Innovation: Addressing Gaps in Immuno-Inflammatory Markets”, in New York on October 14, 2025

Sep 30, 2025, 7:00 AM EDT - 6 weeks ago

Aclaris Therapeutics to Host In-Person and Webcast R&D Day, “Patient Focused Innovation: Addressing Gaps in Immuno-Inflammatory Markets”, in New York on October 14, 2025

Aclaris Therapeutics Announces Late-Breaking Abstract and Oral Presentation On ATI-2138 Phase 2a Results at the 2025 European Academy of Dermatology and Venereology (EADV) Congress

Sep 9, 2025, 7:00 AM EDT - 2 months ago

Aclaris Therapeutics Announces Late-Breaking Abstract and Oral Presentation On ATI-2138 Phase 2a Results at the 2025 European Academy of Dermatology and Venereology (EADV) Congress

Aclaris Therapeutics to Participate in Two September Healthcare Conferences

Aug 27, 2025, 8:00 AM EDT - 2 months ago

Aclaris Therapeutics to Participate in Two September Healthcare Conferences

Aclaris Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 7, 2025, 6:59 AM EDT - 3 months ago

Aclaris Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aclaris Therapeutics Announces Positive Top-Line Results from Open-Label Phase 2a Trial of ATI-2138, a Potent and Selective Investigational Inhibitor of ITK and JAK3; Trial Achieves Primary and Key Secondary Endpoints

Jul 29, 2025, 4:01 PM EDT - 3 months ago

Aclaris Therapeutics Announces Positive Top-Line Results from Open-Label Phase 2a Trial of ATI-2138, a Potent and Selective Investigational Inhibitor of ITK and JAK3; Trial Achieves Primary and Key Secondary Endpoints

Aclaris Therapeutics Announces Leadership Transition

Jul 28, 2025, 8:45 AM EDT - 3 months ago

Aclaris Therapeutics Announces Leadership Transition

Aclaris Therapeutics Added to the Russell 2000® and Russell 3000® Indexes

Jun 30, 2025, 9:31 AM EDT - 4 months ago

Aclaris Therapeutics Added to the Russell 2000® and Russell 3000® Indexes

Aclaris Therapeutics to Participate in the H.C. Wainwright Inflammation & Immunology Virtual Conference

Jun 26, 2025, 4:01 PM EDT - 5 months ago

Aclaris Therapeutics to Participate in the H.C. Wainwright Inflammation & Immunology Virtual Conference

Aclaris Therapeutics Initiates Phase 1a/1b Program for its Novel Bispecific Antibody ATI-052

Jun 23, 2025, 6:59 AM EDT - 5 months ago

Aclaris Therapeutics Initiates Phase 1a/1b Program for its Novel Bispecific Antibody ATI-052

Aclaris Therapeutics to Participate in Two June Healthcare Conferences

May 28, 2025, 9:20 AM EDT - 6 months ago

Aclaris Therapeutics to Participate in Two June Healthcare Conferences

Aclaris Therapeutics to Participate in the HC Wainwright “HCW@Home” Series

May 9, 2025, 7:00 AM EDT - 6 months ago

Aclaris Therapeutics to Participate in the HC Wainwright “HCW@Home” Series

Aclaris Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 8, 2025, 6:50 AM EDT - 6 months ago

Aclaris Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Aclaris Therapeutics Appoints Jesse Hall, M.D. as Chief Medical Officer

Apr 29, 2025, 7:00 AM EDT - 7 months ago

Aclaris Therapeutics Appoints Jesse Hall, M.D. as Chief Medical Officer

Aclaris Therapeutics to Participate in Two March Healthcare Conferences

Mar 4, 2025, 7:00 AM EST - 9 months ago

Aclaris Therapeutics to Participate in Two March Healthcare Conferences

New Publication Highlights Unique Properties of ATI-2138, a Potent and Selective Inhibitor of ITK and JAK3

Feb 12, 2025, 6:50 AM EST - 9 months ago

New Publication Highlights Unique Properties of ATI-2138, a Potent and Selective Inhibitor of ITK and JAK3

Aclaris Therapeutics Announces Formation of New Scientific Advisory Board

Jan 30, 2025, 4:01 PM EST - 10 months ago

Aclaris Therapeutics Announces Formation of New Scientific Advisory Board

Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Jan 6, 2025, 4:30 PM EST - 11 months ago

Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Aclaris Stock Rises As Analyst Projects Billions In Sales For New Therapy

Dec 23, 2024, 1:41 PM EST - 11 months ago

Aclaris Stock Rises As Analyst Projects Billions In Sales For New Therapy

Aclaris Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference

Nov 26, 2024, 4:30 PM EST - 1 year ago

Aclaris Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference

Aclaris Stock Soars As Analysts See Fresh Momentum After Strategic Review And Encouraging Promising Pipeline Developments

Nov 19, 2024, 3:27 PM EST - 1 year ago

Aclaris Stock Soars As Analysts See Fresh Momentum After Strategic Review And Encouraging Promising Pipeline Developments

Biosion Announces Exclusive, Global License Agreement with Aclaris Therapeutics on two potential First-in-Class and Best-in-Class Immunology Assets

Nov 18, 2024, 8:50 AM EST - 1 year ago

Biosion Announces Exclusive, Global License Agreement with Aclaris Therapeutics on two potential First-in-Class and Best-in-Class Immunology Assets

Aclaris Therapeutics Announces Exclusive, Global License Agreement with Biosion, Inc., adding Potential Best-in-Class Biologics Assets to Pipeline

Nov 18, 2024, 8:10 AM EST - 1 year ago

Aclaris Therapeutics Announces Exclusive, Global License Agreement with Biosion, Inc., adding Potential Best-in-Class Biologics Assets to Pipeline

Aclaris Therapeutics Announces $80 Million Private Placement

Nov 18, 2024, 8:10 AM EST - 1 year ago

Aclaris Therapeutics Announces $80 Million Private Placement

Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor for the Treatment of Moderate to Severe Atopic Dermatitis

Sep 17, 2024, 7:00 AM EDT - 1 year ago

Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor for the Treatment of Moderate to Severe Atopic Dermatitis

Aclaris Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference

Sep 10, 2024, 7:00 AM EDT - 1 year ago

Aclaris Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference

Aclaris Therapeutics Announces Sale of OLUMIANT® Royalties and Milestones to OMERS Life Sciences for Up to $31.5 Million

Jul 16, 2024, 4:01 PM EDT - 1 year ago

Aclaris Therapeutics Announces Sale of OLUMIANT® Royalties and Milestones to OMERS Life Sciences for Up to $31.5 Million

Rheumatoid Arthritis Market and Epidemiology Forecast 2024-2034 Featuring Analysis of ATI-450 (Aclaris Therapeutics) and Olumiant/Baricitinib (Eli Lilly/Incyte)

Jun 25, 2024, 12:36 PM EDT - 1 year ago

Rheumatoid Arthritis Market and Epidemiology Forecast 2024-2034 Featuring Analysis of ATI-450 (Aclaris Therapeutics) and Olumiant/Baricitinib (Eli Lilly/Incyte)

Aclaris Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Jun 6, 2024, 7:00 AM EDT - 1 year ago

Aclaris Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

American Clinical Research Services Announces Strategic Acquisition of Elixia

May 8, 2024, 6:30 AM EDT - 1 year ago

American Clinical Research Services Announces Strategic Acquisition of Elixia

Aclaris Therapeutics, Inc. (ACRS) Q1 2024 Earnings Call Transcript

May 7, 2024, 9:44 PM EDT - 1 year ago

Aclaris Therapeutics, Inc. (ACRS) Q1 2024 Earnings Call Transcript

Aclaris Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update

May 7, 2024, 4:01 PM EDT - 1 year ago

Aclaris Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update

Flare Therapeutics Appoints Douglas Manion, M.D., FRCP (C) as Chief Executive Officer

Apr 23, 2024, 8:00 AM EDT - 1 year ago

Flare Therapeutics Appoints Douglas Manion, M.D., FRCP (C) as Chief Executive Officer

Aclaris Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update

Feb 27, 2024, 7:00 AM EST - 1 year ago

Aclaris Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update

Aclaris Therapeutics Announces Top-line Results from 4-Week Phase 2b Trial of ATI-1777 for Mild to Severe Atopic Dermatitis

Jan 10, 2024, 7:00 AM EST - 2 years ago

Aclaris Therapeutics Announces Top-line Results from 4-Week Phase 2b Trial of ATI-1777 for Mild to Severe Atopic Dermatitis

Aclaris Therapeutics Provides Corporate Update

Dec 19, 2023, 4:01 PM EST - 2 years ago

Aclaris Therapeutics Provides Corporate Update

Aclaris Therapeutics Announces Patent License Agreement with Sun Pharma for Alopecia

Dec 5, 2023, 4:01 PM EST - 2 years ago

Aclaris Therapeutics Announces Patent License Agreement with Sun Pharma for Alopecia

Aclaris Therapeutics to stop development of rheumatoid arthritis drug

Nov 13, 2023, 7:19 AM EST - 2 years ago

Aclaris Therapeutics to stop development of rheumatoid arthritis drug

Aclaris Therapeutics Announces Top-line Results from 12-Week Phase 2b Trial of Oral Zunsemetinib (ATI-450) for Moderate to Severe Rheumatoid Arthritis and Provides Corporate Update

Nov 13, 2023, 7:00 AM EST - 2 years ago

Aclaris Therapeutics Announces Top-line Results from 12-Week Phase 2b Trial of Oral Zunsemetinib (ATI-450) for Moderate to Severe Rheumatoid Arthritis and Provides Corporate Update

Aclaris Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Corporate Update

Nov 6, 2023, 7:00 AM EST - 2 years ago

Aclaris Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Corporate Update

Aclaris Therapeutics Completes Enrollment in Phase 2b Study of ATI-1777 for Mild to Severe Atopic Dermatitis (ATI-1777-AD-202)

Oct 3, 2023, 7:00 AM EDT - 2 years ago

Aclaris Therapeutics Completes Enrollment in Phase 2b Study of ATI-1777 for Mild to Severe Atopic Dermatitis (ATI-1777-AD-202)

Aclaris Therapeutics: The Many Lives Of This Biopharmaceutical Developer

Sep 28, 2023, 7:18 AM EDT - 2 years ago

Aclaris Therapeutics: The Many Lives Of This Biopharmaceutical Developer

Aclaris Therapeutics to Participate in the 2023 Cantor Global Healthcare Conference

Sep 20, 2023, 7:00 AM EDT - 2 years ago

Aclaris Therapeutics to Participate in the 2023 Cantor Global Healthcare Conference

Aclaris Therapeutics Announces Positive Results from Phase 1 Multiple Ascending Dose Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor

Sep 18, 2023, 7:00 AM EDT - 2 years ago

Aclaris Therapeutics Announces Positive Results from Phase 1 Multiple Ascending Dose Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor

Aclaris Therapeutics Reports Second Quarter 2023 Financial Results and Provides a Corporate Update

Aug 7, 2023, 7:00 AM EDT - 2 years ago

Aclaris Therapeutics Reports Second Quarter 2023 Financial Results and Provides a Corporate Update

Aclaris Therapeutics: Q4 Of 2023 Catalyst Makes This A Must Watch

Jul 11, 2023, 7:31 PM EDT - 2 years ago

Aclaris Therapeutics: Q4 Of 2023 Catalyst Makes This A Must Watch

Aclaris Therapeutics Completes Enrollment in Phase 2b Study of Oral Zunsemetinib (ATI-450) for Moderate to Severe Rheumatoid Arthritis (ATI-450-RA-202)

Jun 13, 2023, 7:01 AM EDT - 2 years ago

Aclaris Therapeutics Completes Enrollment in Phase 2b Study of Oral Zunsemetinib (ATI-450) for Moderate to Severe Rheumatoid Arthritis (ATI-450-RA-202)

Aclaris Therapeutics to Participate in Two June Healthcare Investor Conferences

Jun 2, 2023, 7:00 AM EDT - 2 years ago

Aclaris Therapeutics to Participate in Two June Healthcare Investor Conferences

StockScanners
StockScanners Nov. 15 at 4:17 AM
$ACRS keep watch if this holds above 2.45
0 · Reply
Bionco
Bionco Nov. 14 at 10:50 PM
$ACRS 189k shares changed hands in a single after-hours trade.
0 · Reply
OriginalTradeonrumor
OriginalTradeonrumor Nov. 14 at 9:07 PM
$ACRS picture perfect trading today!! Loving it !!
0 · Reply
StockDaddy68
StockDaddy68 Nov. 14 at 5:58 PM
$ACRS Very nice
0 · Reply
Bionco
Bionco Nov. 14 at 10:35 AM
$ACRS According to the 13G filing from yesterday, Adage sold a total of 2.92 million shares last week, accounting for the elevated trading volume and the stock's decline over four consecutive days.
1 · Reply
swingexpert
swingexpert Nov. 14 at 6:33 AM
$ACRS We need a catalyst for this to move—top-line Phase 1a results aren’t expected until late 2025, so it may trade sideways until then.
0 · Reply
Btolz
Btolz Nov. 13 at 7:59 PM
$ACRS
0 · Reply
Bionco
Bionco Nov. 13 at 4:32 PM
$ACRS Adage Capital Management recently sold approximately 3 million shares, exiting the group of ≥5% owners.
0 · Reply
StockDaddy68
StockDaddy68 Nov. 13 at 11:22 AM
$ACRS
0 · Reply
Sambo87
Sambo87 Nov. 13 at 10:12 AM
$ACRS
0 · Reply
Bionco
Bionco Nov. 12 at 11:41 PM
$ACRS someone bought (or sold)681k shares in after hrs market.
0 · Reply
Bionco
Bionco Nov. 12 at 4:45 PM
$ACRS A handful of shorties began shorting.
0 · Reply
StockDaddy68
StockDaddy68 Nov. 12 at 11:49 AM
$ACRS
0 · Reply
Bionco
Bionco Nov. 11 at 8:53 PM
$ACRS day traders are trying hard to pull the price down at last minutes
0 · Reply
swingexpert
swingexpert Nov. 11 at 8:03 PM
$ACRS Building new base
0 · Reply
Bionco
Bionco Nov. 11 at 7:30 PM
$ACRS a paradise for penny flippers and day traders!
0 · Reply
OriginalTradeonrumor
OriginalTradeonrumor Nov. 11 at 2:35 PM
$ACRS as discussed…aside from any catalysts popping up, this level was very —VERY—much expected ….if you are going to add 2.10-2.15 is a good place to nibble Should close out year in the 2’s
0 · Reply
dibatista
dibatista Nov. 11 at 2:30 PM
$ACRS WTF happened?
0 · Reply
StockDaddy68
StockDaddy68 Nov. 11 at 12:02 PM
$ACRS A little nervous but still long still confident
0 · Reply
Momo7002momo
Momo7002momo Nov. 10 at 8:18 PM
$ACRS and $SCYX buying some more
1 · Reply
flyinghollaender
flyinghollaender Nov. 10 at 8:02 PM
$IRWD monday was also fine. Great start of the week! Bought more $IPSC $ACRS Also playing ER for $PLX on thursday
1 · Reply
StockDaddy68
StockDaddy68 Nov. 10 at 2:33 PM
$ACRS
0 · Reply